SGHT (Sight Sciences) Marketable Securities: $0.00 Mil (As of Mar. 2026)


SGHT Sight Sciences Inc SGHT
72 GF Score
Price $5.33
GF Value $4.51
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Sight Sciences Marketable Securities?

Sight Sciences SGHT +1.43% 72 Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus rates SGHT with a GF Score™ of 72/100 and a GF Value™ of $4.51 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Sight Sciences's Marketable Securities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Sight Sciences  (NAS:SGHT) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Sight Sciences Marketable Securities Related Terms

Sight Sciences Marketable Securities Historical Data

* Premium members only.

The historical data trend for Sight Sciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sight Sciences Marketable Securities Chart

Sight Sciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Sight Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SGHT
72GF Score
Sight Sciences Inc SGHT
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sight Sciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Sight Sciences (SGHT) has a Marketable Securities of $0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sight Sciences and its competitors.
Is Sight Sciences' Marketable Securities too high?
Sight Sciences' current Marketable Securities is $0.00 Mil. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Marketable Securities compare to SENS and LAB?
Sight Sciences' Marketable Securities of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Devices & Instruments company?
A good Marketable Securities depends on the Medical Devices & Instruments industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Sight Sciences and its competitors. Sight Sciences's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.51, compared to a current price of $5.33 — trading 18.2% above its estimated fair value. The current Marketable Securities is $0.00 Mil. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sight Sciences (SGHT) Overvalued in 2026?

Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued. The current stock price of $5.33 is trading 18.2% above its estimated GF Value™ of $4.51. GuruFocus considers Sight Sciences to be Modestly Overvalued.

Key valuation signals for SGHT:

  • Marketable Securities: $0.00 Mil
  • GF Value™: $4.51 vs. price of $5.33 (18.2% above fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sight Sciences Business Description

Address 4040 Campbell Avenue, Suite 100, Menlo Park, CA, USA, 94025
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score

Get the complete analysis for SGHT

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.33
Price
$4.51
GF Value